260 related articles for article (PubMed ID: 19467033)
1. LEKTI-1 in sickness and in health.
Roelandt T; Thys B; Heughebaert C; De Vroede A; De Paepe K; Roseeuw D; Rombaut B; Hachem JP
Int J Cosmet Sci; 2009 Aug; 31(4):247-54. PubMed ID: 19467033
[TBL] [Abstract][Full Text] [Related]
2. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
Meyer-Hoffert U; Wu Z; Schröder JM
PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
[TBL] [Abstract][Full Text] [Related]
3. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.
Fortugno P; Furio L; Teson M; Berretti M; El Hachem M; Zambruno G; Hovnanian A; D'Alessio M
Hum Mol Genet; 2012 Oct; 21(19):4187-200. PubMed ID: 22730493
[TBL] [Abstract][Full Text] [Related]
4. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).
Schechter NM; Choi EJ; Wang ZM; Hanakawa Y; Stanley JR; Kang Y; Clayman GL; Jayakumar A
Biol Chem; 2005 Nov; 386(11):1173-84. PubMed ID: 16307483
[TBL] [Abstract][Full Text] [Related]
6. rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients.
Roedl D; Oji V; Buters JT; Behrendt H; Braun-Falco M
J Dermatol Sci; 2011 Mar; 61(3):194-8. PubMed ID: 21251800
[TBL] [Abstract][Full Text] [Related]
7. hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6.
Egelrud T; Brattsand M; Kreutzmann P; Walden M; Vitzithum K; Marx UC; Forssmann WG; Mägert HJ
Br J Dermatol; 2005 Dec; 153(6):1200-3. PubMed ID: 16307658
[TBL] [Abstract][Full Text] [Related]
8. LEKTI domain 15 is a functional Kazal-type proteinase inhibitor.
Vitzithum K; Lauber T; Kreutzmann P; Schulz A; Sommerhoff CP; Rösch P; Marx UC
Protein Expr Purif; 2008 Jan; 57(1):45-56. PubMed ID: 17936012
[TBL] [Abstract][Full Text] [Related]
9. LEKTI demonstrable by immunohistochemistry of the skin: a potential diagnostic skin test for Netherton syndrome.
Ong C; O'Toole EA; Ghali L; Malone M; Smith VV; Callard R; Harper JI
Br J Dermatol; 2004 Dec; 151(6):1253-7. PubMed ID: 15606522
[TBL] [Abstract][Full Text] [Related]
10. Dichotomous effect of ultraviolet B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes.
Nin M; Katoh N; Kokura S; Handa O; Yoshikawa T; Kishimoto S
J Dermatol Sci; 2009 Apr; 54(1):17-24. PubMed ID: 19118981
[TBL] [Abstract][Full Text] [Related]
11. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients.
Komatsu N; Saijoh K; Jayakumar A; Clayman GL; Tohyama M; Suga Y; Mizuno Y; Tsukamoto K; Taniuchi K; Takehara K; Diamandis EP
J Invest Dermatol; 2008 May; 128(5):1148-59. PubMed ID: 17989726
[TBL] [Abstract][Full Text] [Related]
12. A heterozygous null mutation combined with the G1258A polymorphism of SPINK5 causes impaired LEKTI function and abnormal expression of skin barrier proteins.
Di WL; Hennekam RC; Callard RE; Harper JI
Br J Dermatol; 2009 Aug; 161(2):404-12. PubMed ID: 19438860
[TBL] [Abstract][Full Text] [Related]
13.
Park NJ; Jo BG; Bong SK; Park SA; Lee S; Kim YK; Yang MH; Kim SN
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955819
[TBL] [Abstract][Full Text] [Related]
14. Serine protease inhibitor lymphoepithelial Kazal type-related inhibitor tends to be decreased in atopic dermatitis.
Roedl D; Traidl-Hoffmann C; Ring J; Behrendt H; Braun-Falco M
J Eur Acad Dermatol Venereol; 2009 Nov; 23(11):1263-6. PubMed ID: 19522716
[TBL] [Abstract][Full Text] [Related]
15. New role for LEKTI in skin barrier formation: label-free quantitative proteomic identification of caspase 14 as a novel target for the protease inhibitor LEKTI.
Bennett K; Callard R; Heywood W; Harper J; Jayakumar A; Clayman GL; Di WL; Mills K
J Proteome Res; 2010 Aug; 9(8):4289-94. PubMed ID: 20533828
[TBL] [Abstract][Full Text] [Related]
16. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.
Ishida-Yamamoto A; Deraison C; Bonnart C; Bitoun E; Robinson R; O'Brien TJ; Wakamatsu K; Ohtsubo S; Takahashi H; Hashimoto Y; Dopping-Hepenstal PJ; McGrath JA; Iizuka H; Richard G; Hovnanian A
J Invest Dermatol; 2005 Feb; 124(2):360-6. PubMed ID: 15675955
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.
Fortugno P; Bresciani A; Paolini C; Pazzagli C; El Hachem M; D'Alessio M; Zambruno G
J Invest Dermatol; 2011 Nov; 131(11):2223-32. PubMed ID: 21697885
[TBL] [Abstract][Full Text] [Related]
18. Netherton syndrome: report of two Taiwanese siblings with staphylococcal scalded skin syndrome and mutation of SPINK5.
Chao SC; Richard G; Lee JY
Br J Dermatol; 2005 Jan; 152(1):159-65. PubMed ID: 15656819
[TBL] [Abstract][Full Text] [Related]
19. Recombinant production, purification and biochemical characterization of domain 6 of LEKTI: a temporary Kazal-type-related serine proteinase inhibitor.
Kreutzmann P; Schulz A; Ständker L; Forssmann WG; Mägert HJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Apr; 803(1):75-81. PubMed ID: 15026000
[TBL] [Abstract][Full Text] [Related]
20. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome.
Bitoun E; Micheloni A; Lamant L; Bonnart C; Tartaglia-Polcini A; Cobbold C; Al Saati T; Mariotti F; Mazereeuw-Hautier J; Boralevi F; Hohl D; Harper J; Bodemer C; D'Alessio M; Hovnanian A
Hum Mol Genet; 2003 Oct; 12(19):2417-30. PubMed ID: 12915442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
